SCHEMBL184964

SCHEMBL184964

CCCCNC(=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.76
ALDH1A1 P00352 2/20 0.76
LMNA P02545 2/20 0.76
TSHR P16473 2/20 0.76
ALB P02768 1/20 0.76
TDP1 Q9NUW8 1/20 0.76
FBP1 P09467 12/20 0.72
EPHX2 P34913 2/20 0.60
CYP3A4 P08684 1/20 0.60
THRB P10828 1/20 0.60
NFKB1 P19838 1/20 0.60
HTR2A P28223 1/20 0.60
CYP2C19 P33261 1/20 0.60
ADRA1A P35348 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL28260710 0.98 CYP2C9 (0.74) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL11049679 0.95 CYP2C9 (0.69) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL28534045 0.94 EPHX2 (0.68) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL19271872 0.94 EPHX2 (0.68) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL6464356 0.91 CYP2C9 (0.72) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL2290886 0.90 ALDH1A1 (0.72) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL5931108 0.89 FBP1 (0.70) CYP2C9ALDH1A1LMNATSHRALB
SCHEMBL1478625 0.87 CYP2C9 (0.74) CYP2C9ALDH1A1LMNATSHRALB
Tolbutamide SCHEMBL1536920 0.86 ALDH1A1 (1.00) CYP2C9ALDH1A1LMNATSHRALB
Tolbutamide SCHEMBL15918 0.86 ALDH1A1 (1.00) CYP2C9ALDH1A1LMNATSHRALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2449 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12208071-B2 Glucagon receptor antagonists LIGAND PHARMACEUTICALS INCORPORATED (US) 2025-01-28 US claimed
US-12186329-B2 Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-01-07 US claimed
US-20240316048-A1 Prevention of Pancreatic Cell Degeneration MELIOR PHARMACEUTICALS I, INC. 2024-09-26 US claimed
US-12070461-B2 Methods and formulations for modulating Lyn kinase activity and treating related disorders MELIOR PHARMACEUTICALS I, INC. (US) 2024-08-27 US claimed
CN-117203324-A Novel yeast strains and their use in controlling plant pathogens 爱农创投有限公司 2023-12-08 CN claimed
US-20230263821-A1 Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors UNIVERSITY OF MARYLAND, BALTIMORE 2023-08-24 US claimed
CN-115825256-A Detection method for rapidly determining various pesticide residues in chicken 中山海关技术中心 2023-03-21 CN claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
CN-114568442-A Blend of a bio-stimulant based on folate impurity 10 and an agrochemical of interest UPL有限责任公司 2022-06-03 CN claimed
CN-114292221-A Synthetic method and application of 2-aryl indole compound 河北农业大学 2022-04-08 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
US-6150383-A COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-11-21 US claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-2000027401-A1 COMBINATIONS FOR DIABETES WHICH CONTAIN A SULFONYLUREA, A GLITAZONE AND A BIGUANIDE WARNER-LAMBERT COMPANY (US) 2000-05-18 WO claimed
CN-1244801-A Sulfonylurea-glitazone synergistic combinations for diabetes WARNER LAMBERT CO (US) 2000-02-16 CN claimed
US-6011049-A Combinations for diabetes WARNER-LAMBERT COMPANY (US) 2000-01-04 US claimed
EP-0957923-A1 SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES WARNER-LAMBERT COMPANY (US) 1999-11-24 EP claimed
US-5972973-A SYNERGISTIC MIXTURE; GLUCOSE CONTROL WARNER-LAMBERT COMPANY (US) 1999-10-26 US claimed
US-5859037-A MIXTURE SYNERGISTIC FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS IN HUMANS, WHICH ALSO IMPROVES GLYCEMIC CONTROL WARNER-LAMBERT COMPANY (US) 1999-01-12 US claimed
WO-1998036755-A1 SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES WARNER LAMBERT COMPANY (US) 1998-08-27 WO claimed